Results 161 to 170 of about 32,386 (229)

Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 2, Page 503-507, February 2026.
Serena Yun‐Chen Tsai, Ashwin N. Ananthakrishnan, Harland S. Winter, Kevin Sheng‐Kai Ma   +3 more
wiley   +1 more source

Sex Differences in Response and Persistence to Biologic Therapy in Psoriatic Arthritis: A 52‐Week Analysis With Extended Long‐Term Outcomes

The Journal of Dermatology, Volume 53, Issue 2, Page 219-230, February 2026.
ABSTRACT Psoriatic arthritis (PsA) is a chronic immune‐mediated disease with heterogeneous joint and skin manifestations. Although biologic therapies targeting TNFα, IL‐17, and IL‐23 have transformed PsA management, sex‐specific differences in efficacy and treatment persistence remain underexplored.
Keita Ohyachi, Saori Takamura, Kanade Iino, Souichiro Saito, Mizuki Takeuchi, Tomoo Fukuda   +5 more
wiley   +1 more source

Sequential Folliculitis, Paraspinal Myositis, and Septic Arthritis Due to Hematogenous Staphylococcus aureus Infection in a Patient Receiving Adalimumab Therapy. [PDF]

Cureus
Burton E, Haller W.
europepmc   +1 more source

S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 270-282, February 2026.
Summary The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent ...
Alexander Nast, Andreas Altenburg, Matthias Augustin, Frank Bachmann, Wolf‐Henning Boehncke, Markus Cornberg, Hilte Geerdes‐Fenge, Brit Häcker, Peter Härle, Joachim Klaus, Michaela Köhm, Arno Köllner, Ulrich Mrowietz, Hans‐Michael Ockenfels, Antonia Pennitz, Sandra Philipp, Thomas Richter, Thomas Rosenbach, Tom Schaberg, Martin Schlaeger, Gerhard Schmid‐Ott, Michael Sebastian, Karisa Thölken, Ralph von Kiedrowski, Uwe Willuhn, Christoph Zeyen   +25 more
wiley   +1 more source

Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease. [PDF]

Pharmaceuticals (Basel)
Lee J, Chung YR, Kim HR, Song JH.
europepmc   +1 more source

S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditäten

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 270-284, February 2026.
Zusammenfassung Der vorliegende Teil 2 der aktualisierten S3‐Leitlinie zur Therapie der Psoriasis vulgaris bietet Empfehlungen zur Therapieauswahl in besonderen klinischen Situationen sowie bei Vorliegen von Komorbidität. Ein Schwerpunkt des Updates liegt im Kapitel Screening auf Tuberkulose sowie in der Therapieauswahl und im Management bei latenter ...
Alexander Nast, Andreas Altenburg, Matthias Augustin, Frank Bachmann, Wolf‐Henning Boehncke, Markus Cornberg, Hilte Geerdes‐Fenge, Brit Häcker, Peter Härle, Joachim Klaus, Michaela Köhm, Arno Köllner, Ulrich Mrowietz, Hans‐Michael Ockenfels, Antonia Pennitz, Sandra Philipp, Thomas Richter, Thomas Rosenbach, Tom Schaberg, Martin Schlaeger, Gerhard Schmid‐Ott, Michael Sebastian, Karisa Thölken, Ralph von Kiedrowski, Uwe Willuhn, Christoph Zeyen   +25 more
wiley   +1 more source

Adalimumab as a Potential Therapeutic Option for Metastatic Crohn's Disease With Genital Lesions and Edema: A Case Report. [PDF]

Clin Case Rep
Haghshenas H, Darban B, Bagherzadeh MA, Karimi M, Ataollahi M.   +4 more
europepmc   +1 more source

Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

International Journal of Dermatology, Volume 65, Issue 2, Page 289-298, February 2026.
ABSTRACT Background Secukinumab, a fully human, monoclonal antibody targeting interleukin‐17A, is approved for moderate‐to‐severe HS in adults. This study evaluated pharmacokinetics (PK), high‐sensitivity C‐reactive protein (hsCRP) changes, and safety of secukinumab over 52 weeks in SUNSHINE and SUNRISE Phase 3 trials.
Afsaneh Alavi, Ziad Reguiai, Gregor B. E. Jemec, Alice B. Gottlieb, Magdalena B. Wozniak, Lorenz Uhlmann, Heng Fan, Angela Llobet Martinez, Gerard Bruin, Nicolas Thomas, Ivette Alarcon, Bruno Bieth, Shoba Ravichandran, Alexa B. Kimball   +13 more
wiley   +1 more source

Adalimumab-Associated Transverse Myelitis Revealing Relapsing-Remitting Multiple Sclerosis in a Patient With Crohn's Disease: A Case Report. [PDF]

Cureus
Gawargeous SS, Elsahy T.
europepmc   +1 more source

Longitudinal Comparison of Calprotectin and C-Reactive Protein in Rheumatoid Arthritis: Real-World Evidence Across Three Targeted Therapies. [PDF]

Diagnostics (Basel)
Fassio A, Galvagni I, Sartoris S, Cassandrini DA, Aldegheri F, Rossini M, Pollastri F, Adami G, Gatti D, Somma R, Appoloni M, Carletto A, Bronte V, Arcolaci A.   +13 more
europepmc   +1 more source